The overexpression of human apurinic/apyrimidinic (AP) endonuclease 1 (APE1/Ref-1), a key enzyme in the DNA base excision repair (BER) pathway, is often associated with tumor cell resistance to various anticancer drugs. In this study, we examined the molecular basis of transcriptional regulatory (nonrepair) function of APE1 in promoting resistance to certain types of drugs. We have recently shown that APE1 stably interacts with Y-box-binding protein 1 (YB-1), and acts as its coactivator for the expression of multidrug resistance gene MDR1, thereby causing drug resistance. In this study, we show, to the best of our knowledge, for the first time that APE1 is stably associated with the basic transcription factor RNA polymerase II (RNA pol II) and the coactivator p300 on the endogenous MDR1 promoter. The depletion of APE1 significantly reduces YB-1-p300 recruitment to the promoter, resulting in reduced RNA pol II loading. Drug-induced APE1 acetylation, which is mediated by p300, enhances formation of acetylated APE1 (AcAPE1)-YB-1-p300 complex on the MDR1 promoter. Enhanced recruitment of this complex increases MDR1 promoter-dependent luciferase activity and its endogenous expression. Using APE1-downregulated cells and cells overexpressing wild-type APE1 or its nonacetylable mutant, we have demonstrated that the loss of APE1's acetylation impaired MDR1 activation and sensitizes the cells to cisplatin or etoposide. We have thus established the basis for APE1's acetylation-dependent regulatory function in inducing MDR1-mediated drug resistance.
Introduction
The multifunctional mammalian apurinic/apyrimidinic (AP) endonuclease 1 (APE1) has a central role in the DNA base excision repair (BER) pathway for repairing damaged bases, abasic (AP) sites and their oxidation products generated in the genome either spontaneously or after excision of oxidized and alkylated bases by DNA glycosylases (Doetsch and Cunningham, 1990; Demple and Harrison, 1994; Matsumoto and Kim, 1995; Singhal et al., 1995; Mitra et al., 2002; Izumi et al., 2003; Fan and Wilson, 2005) . Unrepaired AP sites and DNA strand breaks induce apoptosis and cytotoxicity (Loeb and Preston, 1986) . Besides its repair function, the mammalian APE1 possesses two unique and apparently distinct transcriptional regulatory activities that require its nonconserved N-terminal domain (Evans et al., 2000; Izumi et al., 2005; Bhakat et al., 2009; Tell et al., 2009) . APE1 was identified as a reductive activator of c-Jun in vitro and named redox effector factor-1 (Ref-1; and was subsequently shown to activate several other transcription factors e.g., nuclear factor-kB, hypoxia-inducible factor 1-a, p53, Pax5, Pax8 and c-Myb, presumably through its redox activity Jayaraman et al., 1997; Evans et al., 2000) . APE1 could also act as a trans-acting factor that was discovered in the trans-acting complex that binds to the negative Ca 2 þ response elements (nCaRE-A and B) during Ca 2 þ -dependent downregulation of the parathyroid hormone (PTH) gene (Okazaki et al., 1994) . The presence of the nCaRE-B element and binding of APE1 to this element was also shown in the human renin gene promoter (Fuchs et al., 2003) . Thus, APE1's role as a regulatory factor in diverse trans-acting complexes involved in the activation or repression of various genes were documented (Bhakat et al., 2009) . We discovered acetylation of human APE1 at Lys6 and Lys7 by the histone acetyltransferase activity of p300 (Bhakat et al., 2003a) , and that a significant fraction of APE1 is normally present in the acetylated form (AcAPE1) in many cell lines (Chattopadhyay et al., 2008; Bhakat et al., 2009; Bhattacharyya et al., 2009) . The acetylation of APE1 is regulated by the deacetylase activity of SIRT1 both in cells and in vitro (Yamamori et al., 2010) and SIRT1-mediated deacetylation of APE1 enhances its association with X-ray repair cross-complementing group 1 that regulates its BER activity (Yamamori et al., 2010) . It seems that APE1 is in dynamic equilibrium between its acetylated and unmodified state and the fraction of APE1 that is acetylated varies among different tumor cell lines (Bhakat et al., 2009) . We showed that APE1 acetylation stimulates formation of the nCaRE-B complex, which contains hnRNP-L and histone deacetylase 1, leading to repression of the PTH gene (Kuninger et al., 2002; Bhakat et al., 2003a) . Similarly, Crowe and colleagues in collaboration with us have recently shown that Helicobacter pylori infection induces acetylation of APE1 in gastric epithelial cells; AcAPE1 suppresses Bax expression, and modulates p53-dependent apoptosis of H. Pyroli-infected cells (Bhattacharyya et al., 2009 ). Furthermore, we have shown that early growth response 1-mediated activation of phosphoinositol phosphatase and tensin homolog (PTEN) gene is dependent on APE1 acetylation (Fantini et al., 2008) . Thus, we have established a new role of acetylation-mediated transcriptional regulatory function of APE1 in the regulation of diverse genes. APE1 was also observed to be ubiquitinated at multiple lysine residues in the N-terminal region (Busso et al., 2009) .
APE1 is often overexpressed in tumor cells, and its altered level or intracellular distribution has been observed in various cancer tissues, including the ovarian, cervical, prostate, glioma, head and neck, and non-small-cell lung carcinomas Evans et al., 2000; Kelley et al., 2001; Robertson et al., 2001) . The overexpression of APE1 is invariably associated with resistance to various anticancer drugs; its downregulation or functional impairment sensitizes cells to diverse genotoxic agents, including methyl methanesulfonate, H 2 O 2 , bleomycin, temozolomide, bis-chloronitrosourea, etoposide, cisplatin and doxorubicin (Robertson et al., 1997; Wang et al., 2004; Bobola et al., 2005; Fishel and Kelley, 2007; Chattopadhyay et al., 2008; Jiang et al., 2008; Bapat et al., 2009; McNeill et al., 2009) . Although APE1-dependent repair of the cytotoxic lesions induced by some of these agents, for example, methyl methanesulfonate or H 2 O 2 could explain enhanced sensitivity to some chemicals, the DNA damage induced by many other drugs, such as etoposide or doxorubicin, is not repaired through APE1-mediated BER pathway. Hence, the higher sensitivity to these drugs cannot be explained by the loss of APE1's DNA repair function. Consequently, at least in these cases, the loss of APE1's regulatory function is probably responsible for drug sensitivity. In support of this possibility, we have recently shown that APE1 stably interacts with YB-1, a major transcription factor for the activation of multidrug resistance gene MDR1 (Chattopadhyay et al., 2008) . The MDR1 gene product, P-glycoprotein, an N-glycosylated plasma membrane protein and a member of ATP-binding cassette transporters consists of two highly homologous halves each of which contains a transmembrane domain with several membrane-spanning segments and an ATPbinding fold (Germann and Chambers, 1998) . Increased level of this P-glycoprotein in mammalian cells has been observed to be related to ATP-dependent reduced drug accumulation, and this suggests its role as an energydependent drug efflux pump (Germann and Chambers, 1998) . Overexpression of MDR1 confers resistance to a variety of structurally and functionally unrelated antitumor drugs, such as vincristine, doxorubicin, etoposide and many others (Goldstein et al., 1989; Kohno et al., 1989; Chaudhary and Roninson, 1993; Gottesman and Pastan, 1993; Gottesman et al., 2002) . Both transcriptional activation and gene amplification have been implicated in the acquisition of high levels of MDR1 expression in intrinsic or acquired multidrug resistance in tumor cells (Shen et al., 1986; Kohno et al., 1994) . Furthermore, protein kinase C-mediated phosphorylation of this transporter enhances its drug-efflux and ATPase activity (Yu et al., 1991; Ahmad and Glazer, 1993; Ahmad et al., 1994) .
We showed that APE1 downregulation in cisplatinresistant ovarian cancer cell line A2780 and doxorubicin-resistant breast cancer cell line MCF7 decreases their MDR1 levels and sensitizes these cells to cisplatin or doxorubicin (Chattopadhyay et al., 2008) . However, the molecular basis for YB-1-mediated activation of MDR1 by APE1 and its acetylation is not clear. In this study, we have shown that drug-induced APE1 acetylation enhances YB-1-p300 complex formation on MDR1 promoter. Furthermore, we have shown, to the best of our knowledge, for the first time that APE1 is stably associated with RNA polymerase II (RNA pol II) on the MDR1 promoter and has a key role in both basal and drug-induced recruitment of YB-1-p300 complex and RNA pol II loading. Thus, we have documented a new mechanism by which APE1 and its acetylation regulate MDR1 expression, and provided a molecular basis for sensitization of cells to many drugs through APE1 downregulation.
Results
Stable association of APE1 with p300 and RNA pol II We showed previously that APE1 is acetylated at Lys6/ Lys 7 by p300 (Bhakat et al., 2003a) and this acetylation enhances its association with YB-1 (Chattopadhyay et al., 2008) . We tested stable association between APE1 and p300 by co-immunoprecipitation analysis with nuclear extracts of HEK-293T cells ectopically expressing C-terminally FLAG-tagged full-length or N-terminal 33 amino-acid-deleted (ND33) APE1. Western blot analysis showed the presence of p300 in the FLAG IP of full-length but not of ND33 APE1 (Figure 1a ), indicating that the N-terminal region of APE1 is required for its stable interaction with p300. We further confirmed this interaction by reciprocal analysis and showed the presence of APE1 in the FLAG-p300 IP (Figure 1b) . To test p300-mediated acetylation of APE1 in cells, we downregulated cellular p300 level with small interfering RNA (siRNA) in HEK-293T cells and checked AcAPE1 level with our AcAPE1-specific antibody (Chattopadhyay et al., 2008) . p300 downregulation caused significant decrease in APE1 acetylation without affecting the total APE1 level (Figure 1c) . Several studies have shown that acetylation is a common strategy that p300/ CBP uses to enhance the interaction with nonhistone APE1 acetylation regulates MDR1 expression S Sengupta et al proteins and that the p300 bromodomain is involved in binding to acetylated Lys residues of partner proteins (Mujtaba et al., 2002) . We examined whether APE1 acetylation modulates its interaction with p300. We immunoprecipitated FLAG-tagged wild-type (WT) APE1 or its nonacetylable K6R/K7R (RR) mutant from the nuclear lysates of Trichostatin A-treated (a histone deacetylase inhibitor; Yoshida et al., 1990) or control cells and examined the level of p300 in the IPs. Trichostatin A treatment significantly enhanced the amount of p300 bound to WT but not to RR APE1 (Figure 1d ), indicating that acetylation enhances APE1's association with p300. This was further confirmed by in vitro interaction of unmodified or acetylated APE1 (Figure 1e ) with FLAG-tagged p300. Higher level of bound AcAPE1 compared with the unmodified APE1 was observed (Figure 1f) .
Transcriptional activation by a transcription factor involves recruitment of various coactivators to the specific binding site on DNA, which then directly or indirectly interacts with components of the basal transcription machinery, including RNA pol II and stabilizes the transcription preinitiation complex (Cho et al., 1998) . As p300 is also known to function as a bridging factor connecting sequence-specific transcription factors with the basal transcription machinery (Cho et al., 1998; Neish et al., 1998) including RNA pol II, it is possible that APE1 could be associated with the RNA pol II transcription complex. Western analysis of the FLAG IP of nuclear extract from cells expressing FLAG-APE1 showed the presence of RNA pol II in the immunoprecipitate of full-length but not of ND33 APE1 ( Figure 1a ). As expected, we also showed the presence of RNA pol II in immuno pull-down of FLAG-p300 (Figure 1b) .
Requirement of APE1 in p300-YB-1complex formation and RNA pol II loading on MDR1 promoter Several studies showed that YB-1 is a major transcription factor for MDR1 gene (Kohno et al., 1994; Bargou et al., 1997) . As p300 interacts with both YB-1 and APE1, we questioned whether the interaction between YB-1 and p300 is mediated by APE1. We generated an HEK-293T cell line stably expressing APE1 siRNA ( APE1siRNA HEK-293T) driven by doxycycline (Dox)-inducible promoter as described previously (Vascotto et al., 2009) . After 7-10 days of Dox treatment, endogenous APE1 expression was minimal compared with cells expressing control siRNA (Figure 2a ). We transfected APE1-downregulated APE1siRNA HEK-293T cells with p300-FLAG construct and immunoprecipitated the nuclear extracts with anti-FLAG antibody for APE1 acetylation regulates MDR1 expression S Sengupta et al western blot analysis. Significant reduction in the amount of YB-1 bound to p300 was observed in the IP from APE1-downregulated cells compared with control cells (Figure 2b ). These results indicate APE1's requirement in facilitating YB-1-p300 complex formation.
To examine whether APE1-dependent YB-1-p300 complex formation is essential for MDR1 expression, we showed their occupancy on the MDR1 promoter Y-box element by chromatin immunoprecipitation (ChIP) assay in HEK-293T cells with antibodies to APE1, YB-1, p300 or RNA pol II. The amount of immunoprecipitated MDR1 promoter sequence or a coding sequence of this gene distant to the Y-box element was quantified by real-time PCR analysis. Significant enrichment of the MDR1 promoter Y-box element and not of the coding sequence was observed with anti-APE1, anti-p300, anti-YB-1 or anti-RNA pol II antibody as compared with control IgG (Figure 2c ), indicating that all of these proteins are stably and specifically associated with MDR1 promoter. To establish their simultaneous promoter occupancy, we performed re-ChIP assays using HEK-293T cells transfected with APE1-FLAG construct. Immunoprecipitated chromatin with anti-FLAG antibody or control IgG was secondarily immunoprecipitated with anti-p300, anti-YB-1 or anti-RNA pol II antibody. Significant enrichment of the MDR1 promoter was observed in the FLAG IP as compared with control IgG (Figure 2c ) confirming the association of FLAG-APE1 with MDR1 promoter. Figure 2d provides strong evidence for simultaneous association of p300, YB-1 and RNA pol II with APE1 on the Y-box element on MDR1 promoter because APE1-bound chromatin (FLAG IP) could be immunoprecipitated with the corresponding antibodies as compared with control IgG. 
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We next examined whether APE1 is necessary for the recruitment of p300, YB-1 and RNA pol II on MDR1 promoter. ChIP analysis was performed in cisplatintreated or control APE1-downregulated APE1siRNA HEK-293T cells. Figure 2e shows that APE1 downregulation significantly reduced p300, YB-1 and RNA pol II occupancy on the MDR1 promoter. MDR1 promoter sequence was enriched in the IPs with anti-p300, anti-YB-1 or anti-RNA pol II antibody after cisplatin treatment that was inhibited by APE1 downregulation (Figure 2e ). These results suggest that APE1 is required for both basal and drug-induced enhanced binding/ recruitment of p300 and YB-1 to the Y-box element, which enhances RNA pol II loading on the MDR1 promoter. The functional consequence of reduced binding of YB-1-p300 and RNA pol II loading on MDR1 promoter in APE1-downregulated cells was directly tested by measuring the endogenous MDR1 transcript levels by real-time RT-PCR. As shown in Figure 2f , MDR1 level was increased by three-fold after cisplatin treatment relative to untreated control, which was significantly inhibited in APE1-downregulated cells.
Drug-induced oxidative stress enhances APE1's acetylation and its association with YB-1-p300 on MDR1 promoter Many DNA-damaging agents including chemotherapeutic drugs induce oxidative stress in cells (Kovacic and Osuna, 2000; Kovacic, 2007) . To examine whether oxidative stress enhances the AcAPE1 level, we measured its level in HEK-293T cells after treatment with glucose oxidase (100 ng/ml) or cisplatin (40 ng/ml) for 1 h. Although no significant change in the APE1 polypeptide level was observed, the AcAPE1 level increased significantly after treatment (Figure 3a) . Enhancement of APE1 acetylation after drug treatment may probably be due to oxidative stress-mediated enhancement of histone acetyltransferase activity of p300 (Rahman, 2002) . As genotoxic agents elevate the AcAPE1 level, we examined the effect of oxidative stress on AcAPE1-YB-1-p300 complex formation. We transfected HEK-293T cells with p300-FLAG and treated the cells with glucose oxidase. Western analysis of FLAG IP showed enhanced association of YB-1 with p300 ( Figure 3b) . Although the amount of APE1 associated with p300 under oxidative stress remained unaltered, increased AcAPE1 level in the p300 complex indicates that oxidative stress enhanced APE1 acetylation, which in turn increased the amount of YB-1 in the p300-bound complex (Figure 3b ). We also observed enhanced association of p300 and YB-1 in FLAG-APE1 IP after treatment with glucose oxidase (Figure 3c ) or cisplatin (Figure 3d) . Thus, drug-induced oxidative stress raised the level of AcAPE1 and its association with YB-1-p300. This enhanced the assembly/recruitment of AcAPE1-YB-1-p300 complex to the MDR1 promoter and consequently could help RNA pol II loading.
We then directly tested the presence of AcAPE1 on MDR1 promoter by ChIP analysis. Significant enrichment of MDR1 promoter with anti-AcAPE1 antibody over control IgG (Figure 3e ) indicates AcAPE1's stable association with MDR1 promoter. Furthermore, significantly increased enrichment of the MDR1 promoter in the IP with anti-AcAPE1 antibody relative to anti-APE1 antibody after cisplatin treatment indicates that drug-induced APE1 acetylation enhances its promoter recruitment (Figure 3e ). ChIP assay (Figure 3f ) in HEK-293T cells transfected with FLAGtagged WT APE1, RR, acetylation mimic K6Q/K7Q (QQ) or ND33 APE1 constructs with anti-FLAG antibody shows that replacing lysine with acetylation mimic glutamine did not affect APE1's association with MDR1 promoter; but changing lysine residues to nonacetylable arginine significantly reduced its promoter association. Furthermore, ND33 abolished APE1's promoter association. Together, these data suggest that APE1 acetylation enhances its recruitment on the MDR1 promoter. p300-mediated APE1 acetylation enhances Y-box-dependent MDR1 promoter activity To evaluate the functional consequence of APE1 acetylation and its enhanced binding with p300 and YB-1 on its transcriptional coactivator function, we performed MDR1 promoter-dependent luciferase assay and real-time RT-PCR assay to measure endogenous MDR1 transcript level. We examined the effect of overexpression of WT APE1, acetylation mimic QQ, nonacetylable RR or ND33 APE1 mutants. Figure 4a shows that overexpression of WT or QQ APE1 but not RR or ND33 APE1 mutant significantly enhanced MDR1 promoter activity, indicating that APE1 acetylation is required for this activity. Figure 4b shows that although ectopic expression of WT or QQ APE1 increased endogenous MDR1 expression by more than two-fold relative to empty vector, the RR or ND33 mutant had no significant effect. To further evaluate the effect of APE1 acetylation, we examined the effect of p300 level on MDR1 promoter activity. Figure 4a shows that p300 overexpression activated the MDR1 promoter. To confirm that p300-mediated activation of the MDR1 promoter is mediated through APE1, it was downregulated in APE1siRNA HEK-293T cells before cotransfection with MDR1 promoter-reporter and p300 expression plasmids. As predicted, APE1 downregulation significantly reduced MDR1 promoter activity compared with the control cells (Figure 4c ). p300 overexpression had less stimulatory effect in APE1-downregulated cells, confirming that p300-mediated activation of MDR1 promoter is dependent on the APE1 level (Figure 4c) . Similarly, p300 overexpression significantly increased MDR1 transcript level in Doxuntreated cells relative to empty vector, but had less effect in APE1-downregulated cells (Figure 4d) . Moreover, although overexpression of p300 or WT APE1 individually activated the MDR1 promoter, simultaneous overexpression of p300 and WT, but not of RR, had a synergistic effect (Figure 4e ). These results confirm the acetylation-dependent regulatory role of (Figures 5c, d and e) . Next, clonogeneic survival assays were performed in control and APE1 knockdown cells to measure the cytotoxicity to cisplatin and etoposide. Figures 6a and c show that downregulation of APE1 significantly enhanced sensitivity to cisplatin and etoposide as compared with untreated control, which support our earlier observation (Chattopadhyay et al., 2008) . Dox treatment itself did not affect the survival of the cells with control siRNA (data not shown). In addition, although ectopic overexpression of WT APE1 or QQ mutant increased resistance to drug-induced cytotoxicity, the RR mutant did not confer resistance to these drugs (Figures 6b and  d) . These results indicate that acetylation-mediated transcriptional regulatory function of APE1 has a critical role in protecting the cells from cisplatin-or etoposide-induced cytotoxicity.
Discussion
Although various mechanisms of drug resistance, including alterations of glutathione-mediated detoxification and enhanced DNA repair (Kaina et al., 2001; Kaina and Christmann, 2002) , have been identified in different cancer cell lines, resistance to many common anticancer drugs often occurs due to enhanced expression of MDR1 and other ATP-binding cassette Figure 3 Oxidative stress enhances APE1's acetylation and its association with YB-1-p300 on MDR1 promoter. (a) HEK-293T cells were treated with 100 ng/ml of Glucose oxidase (GO) or 40 mg/ml of cisplatin for 1 h, and 5 h later the AcAPE1, APE1 or b-actin levels in the whole cell extracts were measured by western blot analysis. (b) HEK-293T cells transfected with FLAG-tagged p300 were treated with GO (100 ng/ml) for 1 h, and 5 h later, nuclear lysates were prepared and immunoprecipitated with anti-FLAG antibody. Western analysis of the IPs with anti-YB-1, anti-AcAPE1, anti-APE1 or anti-FLAG antibody; YB-1 and APE1 levels in the lysates (lower panels). (c, d) HEK-293T cells transfected with FLAG-tagged APE1 were treated with GO (100 ng/ml) or cisplatin (40 mg/ml) as above, nuclear lysates were prepared and immunoprecipitated with anti-FLAG antibody. Western blot analysis of the IPs with anti-p300, anti-YB-1 or anti-FLAG antibody; p300 and YB-1 levels in the lysates (lower panels). APE1 acetylation regulates MDR1 expression S Sengupta et al transporter proteins in intrinsically drug-resistant cancer cells, and in many tumors that acquire drug resistance after chemotherapy (Gottesman and Pastan, 1993; Gottesman et al., 2002; Ambudkar et al., 2005) . These transporters reduce intracellular drug concentration by acting as efflux pumps. Several studies have shown that MDR1 expression is often upregulated due to promoter activation by YB-1 after drug treatment (Kohno et al., 1989 (Kohno et al., , 1994 Chaudhary and Roninson, 1993) . Our earlier study showed that APE1 stably interacts with YB-1 and enhances YB-1's binding to Y-box element on the MDR1 promoter leading to its activation (Chattopadhyay et al., 2008) . In this study, we have shown that APE1 is associated with RNA pol II on the endogenous MDR1 promoter and it is required for both basal and drug-induced recruitment of YB-1-p300 complex to the promoter for facilitating RNA pol II loading. Furthermore, our data suggest that drug-induced p300-mediated APE1 acetylation enhances assembly/recruitment of AcAPE1-YB-1-p300 complex on the promoter and has a critical role in enhancing MDR1 expression. Thus, our study for the first time has provided the basis for nonrepair function of APE1 for facilitating MDR1 expression.
Some earlier studies showed that APE1 stimulates the DNA binding of several transcription factors through its redox regulatory function. Initial studies suggested Cys65 of human APE1/Ref-1 (Cys64 of mouse APE1/ Ref-1) to be critical for redox regulation (Walker et al., 1993) ; however, subsequent analyses showed that neither Cys65 nor other cysteine residues are involved in redox regulation (Ordway et al., 2003; Ando et al., 2008) . We observed that the C65S and C138S mutants behaved similar to WT APE1 in modulating YB-1- APE1 acetylation regulates MDR1 expression S Sengupta et al dependent MDR1 promoter activity (Chattopadhyay et al., 2008) , suggesting that APE1's redox activity may not be involved in MDR1 activation. YB-1, a transcriptional regulator (Kohno et al., 2003) , binds to the cognate Y-box element and recruits p300/CBP (Higashi et al., 2003) . We showed earlier that APE1 stably interacts with YB-1 and its acetylation enhances its binding to Y-box sequence. The observation that deletion of the N-terminal 33 amino acids, which are essential for YB-1 binding (Chattopadhyay et al., 2008) , abolished APE1's promoter association, indicates that this interaction is essential for promoter recruitment. Our ChIP results provided strong evidence for simultaneous MDR1 promoter occupancy of APE1, YB-1, p300 and RNA pol II. We have shown that APE1 downregulation reduced recruitment of the YB-1-p300 complex and of RNA pol II loading on the promoter. It seems likely that the transcriptional activator YB-1 recruits coactivators p300 and APE1 to the promoter that enhances YB-1-p300 binding to the promoter. This induces unfolding of the chromatin structure presumably through p300's intrinsic histone acetyltransferase activity, and thereby facilitates RNA pol II complex loading. Furthermore, drug-induced enhanced APE1 acetylation and recruitment of AcAPE1-YB-1-p300 complex to the promoter may cause p300 to communicate with the basal transcription machineries near the transcription start site, and thereby stabilize the RNA pol II preinitiation complex. As the Y-box element (À82 to À73) on the MDR1 promoter is quite close to the transcription start site and p300 may function as a bridging factor between the trans-acting complexes and the basal transcription machinery (Neish et al., 1998; Blobel, 2000) , it is likely that APE1 is stably associated with RNA pol II preinitiation complex. Specifically, p300 interacts with the unphosphorylated form of RNA pol II that is competent in forming the transcription preinitiation complex (Cho et al., 1998) . One recent study also showed that APE1 interacts with estrogen alpha receptor and is associated with its endogenous promoter for activation of estrogen-responsive gene expression (Curtis et al., 2009) . In any case, identification of APE1 as a RNA pol II-associated protein and its requirement in facilitating the RNA pol II loading on the promoter in the context of MDR1 expression is a significant finding of this study. 
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It seems that overexpression of both YB-1 and APE1, often observed in tumor cells, is associated with resistance to various drugs by activating MDR1. Our earlier study showed that APE1 downregulation in cisplatin-resistant A2780/100 and doxorubicin-resistant MCF7 MDR1 cell lines decreased their MDR1 levels and enhanced drug sensitivity (Chattopadhyay et al., 2008) . Consistent with this, one recent study has shown that upregulation of MDR1 levels in the breast cancer tissues in mice is associated with their sensitivity to doxorubicin (Pajic et al., 2009 ). Although we do not have direct evidence that APE1 or its acetylation-mediated regulatory function affect drug transport, activation of MDR1 expression by WT APE1 but not its acetylation mutant support its indirect involvement in enhancing export of the drugs. In the event of drug exposure, an immediate increase in the MDR1 level is warranted for enhancing export of the drugs, which could be affected by enhancing APE1 acetylation. However, it is obvious that acetylation of the APE1 is not the sole mechanism for drug resistance; it is a very complex issue considering the interaction of multiple factors. Moreover, the balance between acetyl transferases and deacetylases that control the acetylation of APE1 and other proteins could indirectly regulate drug resistance. Nevertheless, our data show that specific knockdown of endogenous APE1 by conditional expression of siRNA, sensitized cells to cisplatin or etoposide, which could be overcome by WT APE1 or the acetylation mimic QQ mutant but not by the acetylation-deficient RR mutant. Together, these results confirm that resistance to these drugs is primarily dependent on APE1's acetylation-dependent coregulatory function by modulating MDR1 level.
Finally, we stress that this study, to the best of our knowledge, provides the first evidence for the involvement of APE1's transcriptional regulatory function in recruitment of the transcription factors/coactivators and facilitating RNA pol II loading on the promoter, and thus documents a new mechanism by which APE1 and its acetylation controls YB-1-mediated activation of MDR1 gene. Although other factors, such as NF-Y, AP-1 may also modulate MDR1 expression (Jin and Scotto, 1998; Okamura et al., 2004) , we have provided strong evidence for the key role of APE1 and its acetylation in MDR1 activation, suggesting that the transactivation function of APE1 could be used as a new therapeutic target.
Materials and methods
Cell lines, plasmids and transfection HEK-293T cell line was cultured in Dulbecco's modified Eagle medium with high glucose (Gibco-BRL, Carlsbad, CA, USA) APE1 acetylation regulates MDR1 expression S Sengupta et al with 10% fetal calf serum. The HEK-293T cells stably expressing APE1 siRNA or control siRNA under doxycyclineinducible promoter were generated as described previously (Vascotto et al., 2009) by selection with blasticidin (Gibco-BRL; 5 mg/ml) and zeocine (Gibco-BRL; 100 mg/ml). The APE1 siRNA-expressing HEK-293T clone ( APE1siRNA HEK-293T) that showed maximum APE1 knockdown by treatment with Dox (Sigma, St Louis, MO, USA) was used in subsequent experiments. Cells were transfected using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). pCMV 5.1 FLAG expression plasmids for WT, RR and ND33 APE1 and p300 have been described previously (Bhakat and Mitra, 2000; Chattopadhyay et al., 2008) . The pCMV 5.1 FLAG-tagged QQ APE1 expression plasmid was generated by site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The p300 siRNA used has been described previously (Bhakat et al., 2006) .
Co-immunoprecipitation and western analysis
Immunoprecipitation was carried out with mouse anti-FLAG M2 antibody-conjugated agarose beads (Sigma) in nuclear extracts of cells transfected with FLAG-tagged constructs as described previously (Bhakat et al., 2006; Das et al., 2007; Chattopadhyay et al., 2008) . The immunoprecipitated proteins were resolved in SDS-PAGE and identified by western blot analysis with the indicated antibodies: rabbit a-APE1 (Ramana et al., 1998) , rabbit a-AcAPE1 (Chattopadhyay et al., 2008) , rabbit a-YB-1 (Das et al., 2007; Chattopadhyay et al., 2008) , rabbit a-p300 (N15; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit a-RNA pol II (N20; Santa Cruz Biotechnology), mouse a-FLAG (M2; Sigma) and mouse a-b-actin (AC15; Sigma).
Luciferase assay
Cells were cotransfected with MDR1 promoter reporter constructs (Chattopadhyay et al., 2008) and the expression plasmids for WT, RR, QQ or ND33 APE1 and p300. Luciferase activity in the cells extracts was measured in a luminometer (AutoLumant LB 953; Berthold, Oak Ridge, TN, USA) using the luciferase assay kit (Promega, Madison, WI, USA). The luciferase activity was normalized with respect to total protein content of the lysates.
RNA isolation and real-time RT-PCR assay
Total RNA was isolated from cells with Qiagen (Valencia, CA, USA) RNeasy mini kit followed by DNase 1 (NEB, Ipswich, MA, USA) treatment and complementary DNA synthesis using Superscript III first-strand synthesis kit (Invitrogen). MDR1 expression in the samples were analyzed by SYBR GREEN-based real-time PCR (7000 Fast Real-Time PCR System; Applied Biosystems, Carlsbad, CA, USA) using SYBR Premix Ex Taq (TaKaRa, Madison, WI, USA) and primers appropriate for MDR1 (forward: 5 0 -CCCATCATTG CAATAGCAGG-3 0 and reverse: 5 0 -TGTTCAAACTTCTGC TCCTGA-3 0 ) or hypoxanthine phosphoribosyltransferase 1 expression (HPRT1; internal control; primer sequences: RealTimePrimers.com, Elkins Park, PA, USA).
In vitro acetylation and binding assay Recombinant APE1 (2 mg; Mantha et al., 2008) was acetylated with recombinant p300 histone acetyltransferase domain polypeptide in the presence of 1 mM acetyl Coenzyme-A as described previously (Bhakat et al., 2003b) . Acetylated or unmodified APE1 (100 ng) was incubated with p300 FLAG IP beads and eluted with SDS Laemmli buffer for western blot analysis with anti-APE1 or anti-FLAG antibodies.
ChIP assay
ChIP assay was performed using Magna chromatin immunoprecipitation assay kit (Upstate, Billerica, MA, USA) with the following antibodies: a-RNA pol II (N20), a-p300 (N15), a-YB-1, a-APE1 (Novus Biologicals, Littleton, CO, USA), a-AcAPE1, a-FLAG (M2) or control IgG (Santa Cruz Biotechnology). The immunoprecipitated purified DNA was then subjected to SYBR GREEN-based real-time PCR with primers (forward: 5 0 -TCTCGAGGAATCAGCATTCA-3 0 and reverse: 5 0 -AAGAGCCGCTACTCGAATGA-3 0 ) for the MDR1 promoter sequence (À138 to þ 18) containing the Y-box element and a sequence of the MDR1 gene distant to the Y-box element (forward: 5 0 -AACTGAGGAGATGGGGCA TA-3 0 and reverse: 5 0 -TGGGAACAAATCACTGATCG-3 0 ). For re-ChIP assay, after the first IP was performed with anti-FLAG antibody or control IgG, the second IP was performed in the eluents with anti-RNA pol II, anti-p300 or anti-YB-1 antibody or control IgG.
Cell cycle assay
Cell cycle studies were performed by flow cytometry using a BD FACSCanto (Becton Dickinson, Franklin Lakes, NJ, USA). About 10 6 cells washed and resuspended in phosphatebuffered saline were fixed in 100% ethanol at À20 1C for 15 min and then rehydrated in phosphate-buffered saline at room temperature. The cells were then stained with 3 mM propidium iodide in Staining buffer containing 100 mM TrisHCl (pH 7.4), 150 mM NaCl, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 0.1% NP40 and 0.2 mg/ml RNase A, incubated at room temperature for 15 min in dark and analyzed on a Becton-Dickinson FACSCanto using an Argon laser (excitation 488 nm). For each sample, 10 000 single events were detected and data analysis was performed using FACSDiva version 6.1.2 software program.
Clonogenic survival assay Endogenous APE1-downregulated APE1siRNA HEK-293T or control cells were plated on 35-mm dishes (B300 cells per dish). Next day, the cells were treated with cisplatin (0-125 mM) or etoposide (0-20 mM) and allowed to grow for 10-14 days until visible colonies appeared. In another set, after APE1 downregulation the cells were transfected with WT, RR or QQ APE1 expression constructs. At 48 h later, the cells were plated on 35-mm dishes and proceeded for testing drug sensitivity. The colonies were fixed with 100% methanol, stained with Giemsa staining solution (1:50) and counted.
